Aligos Therapeutics (ALGS) Competitors $18.20 -0.30 (-1.62%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALGS vs. ASMB, AVIR, URGN, LFCR, NGNE, ATYR, FATE, PYXS, BMEA, and TRVIShould you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Assembly Biosciences (ASMB), Atea Pharmaceuticals (AVIR), UroGen Pharma (URGN), Lifecore Biomedical (LFCR), Neurogene (NGNE), Atyr PHARMA (ATYR), Fate Therapeutics (FATE), Pyxis Oncology (PYXS), Biomea Fusion (BMEA), and Trevi Therapeutics (TRVI). These companies are all part of the "medical" sector. Aligos Therapeutics vs. Assembly Biosciences Atea Pharmaceuticals UroGen Pharma Lifecore Biomedical Neurogene Atyr PHARMA Fate Therapeutics Pyxis Oncology Biomea Fusion Trevi Therapeutics Aligos Therapeutics (NASDAQ:ALGS) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability. Does the media prefer ALGS or ASMB? In the previous week, Assembly Biosciences had 2 more articles in the media than Aligos Therapeutics. MarketBeat recorded 3 mentions for Assembly Biosciences and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.73 beat Assembly Biosciences' score of 0.51 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aligos Therapeutics Positive Assembly Biosciences Positive Which has more volatility & risk, ALGS or ASMB? Aligos Therapeutics has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Is ALGS or ASMB more profitable? Assembly Biosciences has a net margin of -144.05% compared to Aligos Therapeutics' net margin of -1,283.19%. Aligos Therapeutics' return on equity of -114.34% beat Assembly Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Aligos Therapeutics-1,283.19% -114.34% -64.58% Assembly Biosciences -144.05%-121.46%-34.56% Which has preferable valuation and earnings, ALGS or ASMB? Assembly Biosciences has lower revenue, but higher earnings than Aligos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAligos Therapeutics$15.53M4.21-$87.68M-$13.32-1.37Assembly Biosciences$7.16M13.34-$61.23MN/AN/A Do institutionals and insiders believe in ALGS or ASMB? 60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 8.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 5.1% of Assembly Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer ALGS or ASMB? Aligos Therapeutics presently has a consensus target price of $75.00, suggesting a potential upside of 312.09%. Assembly Biosciences has a consensus target price of $35.00, suggesting a potential upside of 133.02%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aligos Therapeutics is more favorable than Assembly Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Assembly Biosciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community believe in ALGS or ASMB? Assembly Biosciences received 216 more outperform votes than Aligos Therapeutics when rated by MarketBeat users. However, 65.85% of users gave Aligos Therapeutics an outperform vote while only 58.98% of users gave Assembly Biosciences an outperform vote. CompanyUnderperformOutperformAligos TherapeuticsOutperform Votes2765.85% Underperform Votes1434.15% Assembly BiosciencesOutperform Votes24358.98% Underperform Votes16941.02% SummaryAligos Therapeutics beats Assembly Biosciences on 9 of the 15 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALGS vs. The Competition Export to ExcelMetricAligos TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.38M$2.93B$5.07B$8.89BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-1.3715.0083.5712.93Price / Sales4.21280.711,220.3088.33Price / CashN/A168.0739.4636.25Price / Book1.304.696.936.25Net Income-$87.68M-$41.63M$119.12M$225.93M7 Day Performance-6.47%-4.73%-1.83%-1.32%1 Month Performance149.66%-6.53%-3.64%0.60%1 Year Performance11.66%25.63%31.64%26.23% Aligos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALGSAligos Therapeutics4.1561 of 5 stars$18.20-1.6%$75.00+312.1%+5.5%$66.38M$15.53M-1.3790ASMBAssembly Biosciences4.1387 of 5 stars$15.02-2.1%$35.00+133.0%+86.5%$97.50M$7.16M0.00100AVIRAtea Pharmaceuticals2.7626 of 5 stars$3.16+0.6%$6.88+117.7%+5.0%$265.21M$351.37M0.0070URGNUroGen Pharma3.78 of 5 stars$11.45+2.6%$48.38+322.5%-7.9%$261.74M$82.71M-3.63200LFCRLifecore Biomedical1.5431 of 5 stars$7.48+5.5%$8.00+7.0%+0.7%$261.10M$128.26M93.50690NGNENeurogene2.936 of 5 stars$15.33-11.0%$60.83+296.8%N/A$255.95MN/A0.0090Analyst ForecastAnalyst RevisionNews CoverageATYRAtyr PHARMA2.8572 of 5 stars$2.99-1.6%$19.25+543.8%N/A$255.18M$350,000.00-3.1856FATEFate Therapeutics3.9121 of 5 stars$2.22+1.8%$6.75+204.1%-14.6%$248.29M$63.53M0.00550Analyst UpgradeNews CoveragePYXSPyxis Oncology1.0178 of 5 stars$3.82-8.2%$9.57+150.6%+165.3%$247.38MN/A-3.7160News CoverageGap UpHigh Trading VolumeBMEABiomea Fusion3.4326 of 5 stars$6.28-2.2%$30.50+385.7%-39.1%$232.65MN/A-1.5750TRVITrevi Therapeutics3.4138 of 5 stars$2.77-7.7%$7.43+168.2%+113.1%$230.60MN/A-6.3020 Related Companies and Tools Related Companies Assembly Biosciences Competitors Atea Pharmaceuticals Competitors UroGen Pharma Competitors Lifecore Biomedical Competitors Neurogene Competitors Atyr PHARMA Competitors Fate Therapeutics Competitors Pyxis Oncology Competitors Biomea Fusion Competitors Trevi Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALGS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
